MX2020004048A - Crystalline forms of lenalidomide. - Google Patents

Crystalline forms of lenalidomide.

Info

Publication number
MX2020004048A
MX2020004048A MX2020004048A MX2020004048A MX2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A
Authority
MX
Mexico
Prior art keywords
lenalidomide
crystalline forms
crystalline
forms
empty
Prior art date
Application number
MX2020004048A
Other languages
Spanish (es)
Inventor
Venkata Raghavendracharyulu Palle
Ramakrishna Parameshwar Bhat
Lankeswararao Matti
Vijaybhaskar Reddy Regalla
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2020004048A publication Critical patent/MX2020004048A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

EMPTY
MX2020004048A 2017-09-27 2018-09-27 Crystalline forms of lenalidomide. MX2020004048A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741034364 2017-09-27
PCT/IB2018/057500 WO2019064222A1 (en) 2017-09-27 2018-09-27 Crystalline forms of lenalidomide

Publications (1)

Publication Number Publication Date
MX2020004048A true MX2020004048A (en) 2020-07-20

Family

ID=65901039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004048A MX2020004048A (en) 2017-09-27 2018-09-27 Crystalline forms of lenalidomide.

Country Status (10)

Country Link
US (2) US11203585B2 (en)
EP (1) EP3687987A4 (en)
JP (1) JP2020535192A (en)
KR (1) KR20200092945A (en)
AU (1) AU2018343244A1 (en)
BR (1) BR112020006051A2 (en)
CA (1) CA3076986A1 (en)
MX (1) MX2020004048A (en)
RU (1) RU2020114885A (en)
WO (1) WO2019064222A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196111A1 (en) * 2020-08-14 2023-06-21 Board of Regents, The University of Texas System Method of producing pharmaceutical cocrystals for additive manufacturing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595492A (en) * 2009-03-02 2013-07-26 Generics Uk Ltd Improved Process for the Preparation of Lenalidomide
WO2012127493A1 (en) * 2011-03-23 2012-09-27 Hetero Research Foundation Polymorphs of lenalidomide
US9540341B2 (en) * 2011-07-19 2017-01-10 Amplio Pharma, Llc Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2014160686A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
WO2014160690A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 4-amino-2-(2.6-dioxopiperidine-3-yl) isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
KR102516638B1 (en) * 2014-08-19 2023-04-03 신톤 비.브이. Process for making crystalline form a of lenalidomide

Also Published As

Publication number Publication date
US11203585B2 (en) 2021-12-21
US20210163442A1 (en) 2021-06-03
KR20200092945A (en) 2020-08-04
EP3687987A4 (en) 2021-03-24
EP3687987A1 (en) 2020-08-05
RU2020114885A (en) 2021-10-27
BR112020006051A2 (en) 2020-10-06
WO2019064222A1 (en) 2019-04-04
AU2018343244A2 (en) 2020-06-04
CA3076986A1 (en) 2019-04-04
JP2020535192A (en) 2020-12-03
US20200347027A1 (en) 2020-11-05
AU2018343244A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2020004287A (en) Processing biomass.
MX2020003425A (en) Treatment of inflammatory disorders.
GEP20227403B (en) Compounds
IL269196A (en) Novel inhibitors
MX2020003421A (en) Methods for the administration of certain vmat2 inhibitors.
MX2020003760A (en) Niraparib formulations.
MX2020003706A (en) Aminoimidazopyridazines as kinase inhibitors.
IN2015DE00625A (en)
MX2020004424A (en) Aerosolisable formulation.
MX2020003754A (en) Method of forming microimage elements.
LT3599836T (en) Feeder
MX2020003617A (en) Wire preparation device.
MX2020004662A (en) Targeted adjusting of the contour using corresponding specifications.
ZA201907529B (en) Feeder
MX2020003578A (en) Edaravone salt.
MX2020004245A (en) Improved stabilizer for polyamides.
MX2020004272A (en) A cartridge configured to form a part of a teatcup, and a teatcup.
MX2020004048A (en) Crystalline forms of lenalidomide.
GB2587987B (en) Host-biome interactions
MX2020003440A (en) Safety net.
MX2020004282A (en) Product packaging.
MX2018009818A (en) Empty
MX2018009437A (en) Empty
MX2020004664A (en) Improved fog-generating device.
MX2020003539A (en) Boosting device.